Description
Glifo 25 mg is an oral medication manufactured by ACME Laboratories Ltd., containing Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It is primarily prescribed for adults with type 2 diabetes mellitus to improve glycemic control when used alongside diet and exercise. Additionally, it has been shown to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease .
Empagliflozin works by inhibiting the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By blocking this transporter, Empagliflozin increases urinary glucose excretion, thereby lowering blood glucose levels. This mechanism also contributes to modest weight loss and a reduction in blood pressure .
The typical starting dose of Glifo is 10 mg once daily, taken in the morning with or without food. Depending on individual response and tolerability, the dose may be increased to 25 mg once daily . It is important to note that Glifo should not be initiated in patients with an estimated glomerular filtration rate (eGFR) less than 45 mL/min/1.73 m²
.png)
.webp)
.jpeg)
.webp)
.jpeg)
.webp)
.jpeg)
.png)
.png)
Change Language